GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
GABBR2
androgen receptor
chemoresistance
cisplatin
urothelial cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
06 Sep 2023
06 Sep 2023
Historique:
received:
22
08
2023
revised:
29
08
2023
accepted:
05
09
2023
medline:
23
10
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
The precise molecular mechanisms responsible for resistance to cisplatin-based chemotherapy in patients with bladder cancer remain elusive, while we have indicated that androgen receptor (AR) activity in urothelial cancer is associated with its sensitivity. Our DNA microarray analysis in control vs. AR-knockdown bladder cancer sublines suggested that the expression of a GABA B receptor GABBR2 and AR was correlated. The present study aimed to determine the functional role of GABBR2 in modulating cisplatin sensitivity in bladder cancer. AR knockdown and dihydrotestosterone treatment considerably reduced and induced, respectively, GABBR2 expression, and the effect of dihydrotestosterone was at least partially restored by an antiandrogen hydroxyflutamide. A chromatin immunoprecipitation assay further revealed the binding of AR to the promoter region of
Identifiants
pubmed: 37762034
pii: ijms241813733
doi: 10.3390/ijms241813733
pmc: PMC10530579
pii:
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
GABBR2 protein, human
0
Receptors, Androgen
0
Dihydrotestosterone
08J2K08A3Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Pharmacol. 2017 Sep;92(3):265-277
pubmed: 28424220
Acta Oncol. 2008;47(8):1546-50
pubmed: 18607852
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
World J Gastroenterol. 2023 Jul 28;29(28):4416-4432
pubmed: 37576707
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Bioinformatics. 2014 Jul 1;30(13):1923-5
pubmed: 24578403
Sci Adv. 2021 May 28;7(22):
pubmed: 34049877
Cancer Lett. 2014 Jun 28;348(1-2):100-8
pubmed: 24657659
Cancers (Basel). 2021 Feb 26;13(5):
pubmed: 33652650
Am J Cancer Res. 2014 Sep 06;4(5):461-73
pubmed: 25232488
Am J Surg Pathol. 2019 Dec;43(12):1600-1610
pubmed: 31524642
Clin Cancer Res. 2017 Sep 1;23(17):5003-5014
pubmed: 28490462
Cell Death Dis. 2014 May 29;5:e1257
pubmed: 24874729
J Clin Oncol. 2023 Aug 10;41(23):3881-3890
pubmed: 37549482
J Bone Oncol. 2020 Jul 20;24:100304
pubmed: 32760644
Clin Cancer Res. 2012 Jun 15;18(12):3377-86
pubmed: 22553347
J Exp Pharmacol. 2021 Mar 18;13:303-328
pubmed: 33776489
Transl Androl Urol. 2021 Oct;10(10):4051-4061
pubmed: 34804847
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Cancers (Basel). 2023 Jan 17;15(3):
pubmed: 36765525
Can J Physiol Pharmacol. 2011 Jun;89(6):393-400
pubmed: 21762014
Oncotarget. 2016 Aug 2;7(31):49169-49179
pubmed: 27322140
Cancer Res. 2005 Dec 15;65(24):11437-46
pubmed: 16357152
J Oncol Pharm Pract. 2019 Apr;25(3):648-656
pubmed: 30304985
Front Oncol. 2022 Jul 22;12:912699
pubmed: 35936721
Cancers (Basel). 2022 Feb 09;14(4):
pubmed: 35205613
Mol Cell Endocrinol. 2018 Apr 15;465:73-81
pubmed: 28652170
Int J Mol Sci. 2021 Sep 17;22(18):
pubmed: 34576193
J Transl Med. 2013 Apr 24;11:102
pubmed: 23617850
J Urol. 2012 Jul;188(1):276-86
pubmed: 22608749
J Transl Med. 2018 Apr 11;16(1):96
pubmed: 29642900
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
Eur Urol. 2015 Feb;67(2):241-9
pubmed: 25257030
Cells. 2021 May 11;10(5):
pubmed: 34064926
Cancer Invest. 2007 Oct;25(7):574-83
pubmed: 18027151
Front Oncol. 2022 Aug 18;12:945057
pubmed: 36059697
Am J Clin Oncol. 1985 Feb;8(1):77-80
pubmed: 4039530
Onco Targets Ther. 2019 Dec 31;12:11805-11816
pubmed: 32099386
Int J Mol Sci. 2018 Mar 07;19(3):
pubmed: 29518977
Urol Oncol. 2019 Jul;37(7):492-502
pubmed: 31006613
Cancer Res. 2002 Nov 15;62(22):6467-9
pubmed: 12438237
J Urol. 2001 Jul;166(1):304-10
pubmed: 11435891
Pathol Oncol Res. 2009 Dec;15(4):645-50
pubmed: 19381877
BMC Urol. 2020 Oct 14;20(1):158
pubmed: 33054762
Mol Cancer Ther. 2020 Sep;19(9):1930-1942
pubmed: 32737155
Int J Oncol. 2017 Jan;50(1):75-84
pubmed: 27909718
Cancer Sci. 2020 Sep;111(9):3397-3400
pubmed: 32678492
Eur J Pharmacol. 1993 Mar 23;233(2-3):179-86
pubmed: 8385620
Endocr Relat Cancer. 2011 Jul 04;18(4):451-64
pubmed: 21613411
Oncol Rep. 2019 May;41(5):3111-3118
pubmed: 30864720